BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 19128641)

  • 1. Epigenetic perspective into head and neck cancer through in silico gene expression profiling of histone lysine methyltransferases.
    Biron VL; Dort JC
    J Otolaryngol Head Neck Surg; 2008 Jun; 37(3):366-72. PubMed ID: 19128641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of four histone lysine-methyltransferases in parotid gland tumors.
    Aniello F; Colella G; Muscariello G; Lanza A; Ferrara D; Branno M; Minucci S
    Anticancer Res; 2006; 26(3A):2063-7. PubMed ID: 16827145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dominant negative p63 isoform expression in head and neck squamous cell carcinoma.
    Sniezek JC; Matheny KE; Westfall MD; Pietenpol JA
    Laryngoscope; 2004 Dec; 114(12):2063-72. PubMed ID: 15564824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic regulation of development by histone lysine methylation.
    Dambacher S; Hahn M; Schotta G
    Heredity (Edinb); 2010 Jul; 105(1):24-37. PubMed ID: 20442736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA repair gene expression level in peripheral blood and tumour tissue from non-small cell lung cancer and head and neck squamous cell cancer patients.
    Schena M; Guarrera S; Buffoni L; Salvadori A; Voglino F; Allione A; Pecorari G; Ruffini E; Garzino-Demo P; Bustreo S; Consito L; Bironzo P; Matullo G
    DNA Repair (Amst); 2012 Apr; 11(4):374-80. PubMed ID: 22284908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of TESTIN and its association with cancer history and a tendency toward poor survival in head and neck squamous cell carcinoma.
    Gunduz E; Gunduz M; Beder L; Nagatsuka H; Fukushima K; Sutcu R; Delibas N; Yamanaka N; Shimizu K; Nagai N
    Arch Otolaryngol Head Neck Surg; 2009 Mar; 135(3):254-60. PubMed ID: 19289703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ras mutations and expression in head and neck squamous cell carcinomas.
    Yarbrough WG; Shores C; Witsell DL; Weissler MC; Fidler ME; Gilmer TM
    Laryngoscope; 1994 Nov; 104(11 Pt 1):1337-47. PubMed ID: 7968162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positive correlation of tissue inhibitor of metalloproteinase-3 and death-associated protein kinase hypermethylation in head and neck squamous cell carcinoma.
    Nayak CS; Carvalho AL; Jeronimo C; Henrique R; Kim MM; Hoque MO; Chang S; Jiang WW; Koch W; Westra W; Sidransky D; Califano J
    Laryngoscope; 2007 Aug; 117(8):1376-80. PubMed ID: 17592394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of gene promoter methylation in squamous cell cancer of the head and neck.
    Hasegawa M; Nelson HH; Peters E; Ringstrom E; Posner M; Kelsey KT
    Oncogene; 2002 Jun; 21(27):4231-6. PubMed ID: 12082610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients.
    Rosas SL; Koch W; da Costa Carvalho MG; Wu L; Califano J; Westra W; Jen J; Sidransky D
    Cancer Res; 2001 Feb; 61(3):939-42. PubMed ID: 11221887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma.
    Chung CH; Parker JS; Ely K; Carter J; Yi Y; Murphy BA; Ang KK; El-Naggar AK; Zanation AM; Cmelak AJ; Levy S; Slebos RJ; Yarbrough WG
    Cancer Res; 2006 Aug; 66(16):8210-8. PubMed ID: 16912200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RAR beta2 suppression in head and neck squamous cell carcinoma correlates with site, histology and age.
    Olasz J; Juhász A; Remenár E; Engi H; Bak M; Csuka O; Kásler M
    Oncol Rep; 2007 Jul; 18(1):105-12. PubMed ID: 17549354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MUC1 expression is regulated by DNA methylation and histone H3 lysine 9 modification in cancer cells.
    Yamada N; Nishida Y; Tsutsumida H; Hamada T; Goto M; Higashi M; Nomoto M; Yonezawa S
    Cancer Res; 2008 Apr; 68(8):2708-16. PubMed ID: 18413738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromatin dysregulation associated with NSD1 mutation in head and neck squamous cell carcinoma.
    Farhangdoost N; Horth C; Hu B; Bareke E; Chen X; Li Y; Coradin M; Garcia BA; Lu C; Majewski J
    Cell Rep; 2021 Feb; 34(8):108769. PubMed ID: 33626351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic cancer therapy: Proof of concept and remaining challenges.
    Mund C; Lyko F
    Bioessays; 2010 Nov; 32(11):949-57. PubMed ID: 21154865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Epigenetic Regulation on Head and Neck Squamous Cell Carcinoma.
    Bais MV
    J Dent Res; 2019 Mar; 98(3):268-276. PubMed ID: 30615537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA methylation and cancer.
    Jones PA
    Oncogene; 2002 Aug; 21(35):5358-60. PubMed ID: 12154398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of expression of ZAC/LOT1 in squamous cell carcinomas of head and neck.
    Koy S; Hauses M; Appelt H; Friedrich K; Schackert HK; Eckelt U
    Head Neck; 2004 Apr; 26(4):338-44. PubMed ID: 15054737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3.
    Kunizaki M; Hamamoto R; Silva FP; Yamaguchi K; Nagayasu T; Shibuya M; Nakamura Y; Furukawa Y
    Cancer Res; 2007 Nov; 67(22):10759-65. PubMed ID: 18006819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel integrative methods for gene discovery associated with head and neck squamous cell carcinoma development.
    Smith IM; Mithani SK; Liu C; Chang SS; Begum S; Dhara M; Westra W; Sidranksy D; Califano JA
    Arch Otolaryngol Head Neck Surg; 2009 May; 135(5):487-95. PubMed ID: 19451471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.